Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
Date:11/1/2011

compounds, and the potential therapeutic and commercial potential of LX1031, LX1032, LX1033, LX2931, and LX4211. This press release also contains forward-looking statements relating to Lexicon's partnership discussions with third parties with respect to the development and commercialization of LX1032.  In addition, this press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031, LX1032, LX1033, LX2931, and LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, including with respect to LX1032, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whethe
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
2. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
3. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
4. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
5. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
6. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
7. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
9. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
11. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  Holographic Optical Technologies of ... field of holographic medical imaging, is entering the world ... campaign. Launching on April 20 th , 2015, the ... Pro. The 8-inch and 22-inch displays will allow consumers ... the first time. In addition to the two displays, ...
(Date:3/27/2015)... YORK , March 27, 2015 A new ... Latin America – Chile ... are top targets for IVD firms.  The healthcare ... figures heavily into IVD strategies for the Latin American continent ... to support globally distributed supply operations. However, the country,s regional ...
(Date:3/27/2015)... LONDON , March 27, 2015 ... commercial prospects for leading ophthalmic drug companies  ... the pharma ophthalmic industry ? Visiongain,s brand new ... trends, opportunities and prospects there. Our 242-page ... most lucrative areas in the industry and the future ...
Breaking Medicine Technology:Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7
... 30 Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) ... supporting the safety and efficacy of Caldolor® ( ibuprofen ) ... which was published in the August edition of the peer-reviewed ... decreased pain and morphine use when compared with placebo. ...
... LOUIS, Aug. 30 Recession-driven budget cuts by hospitals and ... AHPI ) throughout fiscal 2010.  The company managed ... overhead and operating costs.  Still, the company reported a loss ... ending June 30, 2010, Allied sales fell about $6 million, ...
Cached Medicine Technology:Pre and Post-Operative Use of Caldolor® (Ibuprofen) Injection Significantly Reduces Pain and Opioid Use in Newly Published Study 2Pre and Post-Operative Use of Caldolor® (Ibuprofen) Injection Significantly Reduces Pain and Opioid Use in Newly Published Study 3Pre and Post-Operative Use of Caldolor® (Ibuprofen) Injection Significantly Reduces Pain and Opioid Use in Newly Published Study 4Pre and Post-Operative Use of Caldolor® (Ibuprofen) Injection Significantly Reduces Pain and Opioid Use in Newly Published Study 5Recession Leads to Sales Decline and Loss for Allied Healthcare Products in Fiscal 2010 2Recession Leads to Sales Decline and Loss for Allied Healthcare Products in Fiscal 2010 3Recession Leads to Sales Decline and Loss for Allied Healthcare Products in Fiscal 2010 4Recession Leads to Sales Decline and Loss for Allied Healthcare Products in Fiscal 2010 5
(Date:3/29/2015)... New York, NY (PRWEB) March 29, 2015 ... testosterone treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) pending in ... has scheduled the litigation’s next Case Management Conference ... indicate that the meeting will address the progress ... men who allegedly experienced heart attacks, strokes and ...
(Date:3/29/2015)... March 29, 2015 “Health is an ... as we learn more about the cannabinoid system … ... March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ new ... endo-healing, is celebrated. Publius, of The Cannabis Papers: A ... Institutes of Health (PubMed) cannabinoid system (CS) articles discussing: ...
(Date:3/28/2015)... Take a bite of warm, gooey pepperoni pizza, and ... the stomach, ready to break down your meal. In ... run amok, triggering a burning sensation in the chest. ... million Americans have heartburn at least once a month. ... it can be stopped. , Heartburn or acid reflux ...
(Date:3/28/2015)... 2015 India Network visitor health ... available to all visitors who purchase the plan before ... are encouraged to purchase the insurance program as soon ... proper coverage for pre-existing medical conditions. Parents and grandparents ... medical conditions with serious consequences to their health. Many ...
(Date:3/28/2015)... 28, 2015 How best to treat ... field in orthopaedic medicine. While diagnostic hip injections are ... the pain etiology, research presented today at the American ... Day suggests that pain relief from this diagnostic injection ... , “Our study looked to assess if the ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 2Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 3Health News:March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ New on the Bryan William Brickner Blog 2Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2
... Regular use of laptop could damage your health and ... other serious orthopedic pain because of poor posture , ... traveling businessmen, students, executives and those who need convenience, ... and laptops soared in India last year. According to ...
... scale clinical trials in order to substantiate preliminary results. ... were a small scale study which not only looked at ... at its potential as a non-surgical penis enlargement product. ... development firm, the penis extender was shown to correct Peyronies ...
... ban on smoking in public places amid protests from bar ... severe and poorly executed. ,'The authorities didn't give ... and restaurants so most people have to resort to smoking ... Reykjavik bar and restaurant, told AFP. ,Due to ...
... of how some abnormal cells can avoid a biochemical program ... the damage, is giving investigators at St. Jude Children's Research ... survive and thrive. ,The St. Jude study also ... to block this backup program would allow that program to ...
... seized in the European Union in 2006, according to EU ... of all fake medicines seized in the EU last year ... three countries are responsible for more than 70 percent of ... fake medicines included Viagra, Cialis and Levitra but also other ...
... into Kerala, tourist resorts and ayurvedic spas are all ready ... is the best time for Ayurvedic treatment. ,Although ... recent years that it has become a huge selling point ... ,According to ayurveda specialists, the monsoon season is the ...
Cached Medicine News:Health News:Regular Use of Laptop Could Seriously Damage Your Health 2Health News:Urologists Begin Clinical Trials on Treatment of Peyronies Disease 2Health News:India Main Source of Counterfeit Medicines Seized in Europe 2Health News:India Main Source of Counterfeit Medicines Seized in Europe 3Health News:Ayurveda Resorts in Kerala Gear Up for the Monsoon Season 2Health News:Ayurveda Resorts in Kerala Gear Up for the Monsoon Season 3
... Dimension cardiovascular ultrasound system is the world's ... fully integrated real-time 4D and multi-dimensional imaging ... member of the Vivid 7 family, provides ... diagnosing heart conditions such as heart failure ...
... Expandable Spinal System is intended for use ... - preloaded on its Delivery System - ... in a reduced configuration of 5 mm ... 15mm (depending on the size selected) once ...
... Rhe Vivid 7 system is GEs ... new level of image quality to echocardiography, ... diagnostic confidence to clinicians.,By listening to customer ... created the first ergonomically-designed cardiovascular system that ...
... Radi invented the guidewire-mounted pressure sensor ... PressureWire5 Sensor is the only sensor ... temperature and flow. With significantly improved ... as your primary guidewire, as well ...
Medicine Products: